Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Micromet Inc. Stories

2012-07-29 22:20:38

SCHLIEREN, Switzerland, July 30, 2012 /PRNewswire/ -- - Cytos Biotechnology Ltd substantially increases its cash by raising CHF 33.58 million through equity and debt - Board of Directors further strengthened by the nomination of Dr. Christian Itin, former President and CEO of Micromet Inc., as a Non-Executive Director - Large global Phase IIb program with CYT003 in allergic asthma planned to start in 2H12 Cytos...

2012-03-07 07:00:00

THOUSAND OAKS, Calif., March 7, 2012 /PRNewswire/ -- Amgen Inc. ("Amgen") (NASDAQ:AMGN) announced today the expiration of the subsequent offering period of the tender offer (the "Offer") by a wholly owned subsidiary, "Merger Sub," to acquire all outstanding shares of common stock of Micromet, Inc. ("Micromet") (NASDAQ:MITI) for $11.00 per share in cash. The subsequent offering period expired at 12:00 midnight, New York City time, at the end of Tuesday, March 6, 2012. The depositary for...

2012-03-02 07:00:00

THOUSAND OAKS, Calif., March 2, 2012 /PRNewswire/ -- Amgen ("Amgen") (NASDAQ: AMGN) announced today that all conditions to the closing of the tender offer (the "Offer") by a wholly owned subsidiary, "Merger Sub", to acquire all outstanding shares of common stock of Micromet, Inc. ("Micromet") (NASDAQ: MITI) for $11.00 per share in cash have been satisfied. The depositary for the Offer has advised Amgen that, as of the expiration of the Offer at 12:00 midnight, New York City time,...

2012-02-03 12:38:00

DALLAS, Feb. 3, 2012 /PRNewswire/ -- Securities lawyers at Goldfarb LLP are investigating whether certain officers and directors of Micromet, Inc. (NASDAQ: MITI) violated shareholder protection laws by agreeing to a tender offer for $11.00 per share to Amgen. Concerned Micromet investors are encouraged to contact securities class action attorney Hamilton Lindley at 877-583-2855 or hlindley@goldfarbllp.com about their rights and remedies for this potentially low buyout. "The Wall Street...

2012-01-27 08:00:00

VANCOUVER, British Columbia, Jan. 27, 2012 /PRNewswire-Asia/ -- Pennystocksinsiders.com (PSI) has issued insider trading reports and Equity Research for the following companies: First Niagara (NASDAQ: FNFG), Micromet (NASDAQ: MITI), Associated Banc (NASDAQ: ASBC), Great Panther Silver (AMEX: GPL), Paramount Gold and Silver (AMEX: PZG) and American Capital (NASDAQ: ACAS). (Logo: http://photos.prnewswire.com/prnh/20111214/HK22486LOGO ) (Read full report by clicking the link below, you may...

2012-01-26 15:01:00

THOUSAND OAKS, Calif., Jan. 26, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) reported total revenue increased 3 percent during the fourth quarter of 2011 to $3,973 million versus $3,841 million in the fourth quarter of 2010. For the full year 2011, total revenue increased 4 percent to $15,582 million from $15,053 million in 2010. Adjusted earnings per share (EPS) were $1.21 for the fourth quarter of 2011, an increase of 3 percent compared to $1.17 for the fourth quarter of 2010. Adjusted...

2012-01-26 07:00:00

THOUSAND OAKS, Calif., and ROCKVILLE, Md., Jan. 26, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Micromet, Inc. (NASDAQ:MITI) today announced that the companies have entered into a definitive merger agreement under which Amgen will acquire Micromet, a biotechnology company founded in Germany with its research and development (R&D) center in Munich and headquarters in Rockville, Md., for $11 per share in cash. The transaction, which values Micromet at approximately...

2010-06-29 07:30:00

BETHESDA, Md., June 29 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), today announced the publication of pre-clinical data in the Proceedings of the National Academy of Sciences (PNAS), demonstrating the potency of new product candidates based on the Company's proprietary BiTE® antibody technology. BiTE antibodies are a new class of agents designed to harness a patient's T cells to kill cancer cells. Results published in PNAS characterize new BiTE antibodies...

2010-06-14 07:30:00

BETHESDA, Md., June 14 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) today announced the presentation of updated results from a Phase 1 trial of the Company's lead product candidate blinatumomab (MT103) in patients with relapsed non-Hodgkin's lymphoma (NHL). A high objective response rate was maintained among patients treated with blinatumomab using an adapted schedule, comparable to that previously reported in patients receiving constant dosing. Blinatumomab is the first in a...

2010-06-14 07:30:00

BETHESDA, Md., June 14 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) today announced the presentation of updated results from a Phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with minimal residual disease (MRD) positive acute lymphoblastic leukemia (ALL). Results of the analysis demonstrate that a prolonged hematologic relapse free survival was observed in patients treated with blinatumomab. As of April 2010, six of nine evaluable,...